{"nctId":"NCT00075946","briefTitle":"Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma","startDateStruct":{"date":"2004-01-23","type":"ACTUAL"},"conditions":["Lymphoma"],"count":545,"armGroups":[{"label":"Arm A: Rituximab Retreatment","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: rituximab"]},{"label":"Arm B: Rituximab Scheduled","type":"EXPERIMENTAL","interventionNames":["Biological: rituximab"]}],"interventions":[{"name":"rituximab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"INCLUSION CRITERIA:\n\n* Histologically confirmed non-Hodgkin's lymphoma, including 1 of the following:\n\n  * Follicular grade 1 or 2\n  * Small lymphocytic\n  * Marginal zone (nodal)\n  * Marginal zone (splenic)\n  * Mucosa-associated lymphoid tissue (MALT)\n* Stage III or IV disease\n* Must meet the following criteria for low tumor burden:\n\n  * No nodal or extranodal mass at least 7 cm\n  * Less than 3 nodal masses greater than 3 cm in diameter\n  * No systemic symptoms or B symptoms\n  * No splenomegaly greater than 16 cm by a computed tomography (CT) scan\n  * No evidence of risk of compression of a vital organ (i.e., ureteral or epidural)\n  * No leukemic phase with greater than 5,000/mm\\^3 circulating lymphocytes\n  * No cytopenias, defined as any of the following:\n\n    * Platelet count less than 100,000/mm\\^3\n    * Hemoglobin less than 10 g/dL\n    * Absolute neutrophil count less than 1,500/mm\\^3\n* At least 1 objective measurable disease parameter\n\n  * Abnormal positron emission tomography (PET) scans will not constitute evaluable disease unless verified by CT scan or other appropriate imaging\n* Age: 18 and over\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Must meet the following criteria for labs:\n\n  * Hematopoietic\n\n    * Absolute neutrophil count at least 1,500/mm\\^3\\*\n    * Hemoglobin at least 10 g/dL\\*\n    * Platelet count at least 100,000/mm\\^3\\*\n    * NOTE: \\*Without growth factor and/or transfusion support\n  * Hepatic\n\n    * Bilirubin no greater than 2 times upper limit of normal (ULN) OR direct bilirubin normal for patients with Gilbert's Syndrome\n    * The aspartate transaminase (AST) and alanine transaminase (ALT) ratio (AST/ALT) no greater than 5 times ULN\n    * Hepatitis B surface antigen negative\n  * Renal\n\n    * Creatinine no greater than 2 times ULN\n\nEXCLUSION CRITERIA:\n\n* Evidence of transformation to a large cell histology\n* Pregnant or nursing. Fertile patients must use effective contraception\n* HIV positive\n* Uncontrolled active infection\n* Other malignancy within the past 2 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* Prior immunotherapy for lymphoma\n* Prior chemotherapy for lymphoma\n* Concurrent chemotherapy\n* Prior radiotherapy for lymphoma\n* Concurrent radiotherapy\n* Concurrent radioimmunotherapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Rituximab Failure (TTRF)","description":"TTRF is defined as the time from randomization until any one of the following criteria are met, and censored at last disease assessment for cases who have not experienced failure (with the cut-off date for final analysis of 11/1/2011): 1. No response (partial response (PR) or complete response (CR)) to rituximab retreatment (Arm A treatment). 2. Time to progression \\< 26 weeks from day 1 of most recent rituximab treatment. 3. Initiation of alternative therapy. 4. Inability to complete protocol therapy (due to adverse events, patient preference, or any other reason, including death).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.92","spread":null},{"groupId":"OG001","value":"4.32","spread":null},{"groupId":"OG002","value":"1.39","spread":null},{"groupId":"OG003","value":"4.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Cytotoxic Therapy (TTFC)","description":"TTFC is defined as the time from randomization to the time of first cytotoxic therapy (chemo and radio therapy), and censored as last follow-up time if no cytotoxic therapy has been used. Since median TTFC was not reached in 3 out of the 4 groups, 3-year TTFC was reported which was defined as the probability of not starting first cytotoxic therapy at 3 years.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":null},{"groupId":"OG001","value":"0.95","spread":null},{"groupId":"OG002","value":"0.72","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Health-related Quality of Life (HRQL) at 6 Month After Randomization","description":"The overall HRQL was measured by the change in Functional Assessment of Cancer Therapy - General (FACT-G) from baseline to 6 months after randomization. The FACT-G is a 27-item assessment used to measure HRQL, specifically, physical, functional, social and emotional well-being. The total score ranges from 0 to 108, with higher scores indicating better HRQL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"12.82"},{"groupId":"OG001","value":"-0.71","spread":"9.38"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":500},"commonTop":["Fatigue"]}}}